Connect with us

China

Letter from NIH Official Admits to Funding Gain-of-Function Research at Wuhan

Published

on

Wuhan Lab

A letter was sent to Republican Representative James Comer from Lawrence A. Tabak of the National Institute of Health (NIH) confirming what many Republicans have concluded about the novel coronavirus pandemic, but have been denied by Fauci and others in the Biden administration.

The letter, sent Wednesday by the top NIH official, admits U.S. taxpayers did indeed fund gain-of-function research on bat coronaviruses in Wuhan. “In keeping with Fauci’s refusal to use ‘gain-of-function,’ Tabak avoids the term, though the work he described matches its commonplace definition precisely,” writes National Review.

Additionally, the letter confirmed the U.S. non-profit EcoHealth Alliance that funneled money from the NIH to the Wuhan Institute of Virology was not transparent about its work. Tabak writes about a “limited experiment” that was conducted to test if “spike proteins from naturally occurring bat coronaviruses circulating in China were capable of binding to the human ACE2 receptor in a mouse model.” The lab mice infected “became sicker” than those infected with the unmodified bat virus.

EcoHealth had filed a “previously unpublished” grant proposal with the NIAID. The proposal was obtained by The Intercept and exposed that $599,000 of the total grant to the Wuhan Institute of Virology was for research figuring out how to make viruses more dangerous and/or infectious.

Additionally, Tabak reveals EcoHealth failed to comply with its reporting responsibilities under the grant, therefore now has five days to submit to NIH “any and all unpublished data” relating to the project for compliance purposes.

National Review writes “Dr. Richard Ebright, biosafety expert and professor of chemistry and chemical biology at Rutgers University, had previously rebutted Fauci’s claim that the NIH ‘has not ever and does not now fund gain of function research in the Wuhan Institute of Virology [WIV]’ as ‘demonstrably false.”

“Ebright told National Review that the NIH-financed work at the WIV ‘epitomizes’ the definition of gain-of-function research, which deals with ‘enhanced potential pandemic pathogen (PPP)’ or those pathogens ‘resulting from the enhancement of the transmissibility and/or virulence of a pathogen.”

You may like

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

China

FDA will work with China to import cancer drugs due to U.S. shortages

Published

on

FinalFDAshutterstock 1044596995

Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.

Foreign Desk News writes:

Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.

“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.

Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.

“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.

Foreign Desk News adds:

The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.

 

You may like

Continue Reading
Advertisement
-->

Trending Now

Advertisement
-->

Trending